Resveratrol inhibition of varicella-zoster virus replication in vitro

Aggarwal, 2004, Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies, Anticancer Res., 24, 2783 Arvin, 2001, Varicella-zoster virus, vol. 2, 2731 Baek, 2002, Resveratrol enhances the expression of non-steroidal anti-inflammatory drug-activated gene (NAG-!) by increasing the expression of p53, Carcinogenesis, 23, 425, 10.1093/carcin/23.3.425 Cao, 2005, Anti-angiogenic activity of resveratrol, a natural compound from medicinal plants, J. Asian Nat. Prod. Res., 7, 205, 10.1080/10286020410001690190 Chen, 2005, Synthesis and anti-inflammatory activity of resveratrol analogs, Chem. Pharm. Bull. (Tokyo), 53, 1587, 10.1248/cpb.53.1587 Cohrs, 1996, Varicella-zoster virus (VZV) transcription during latency in human ganglia: detection of transcripts mapping to genes 21, 29, 62, and 63 in a cDNA library enriched for VZV RNA, J. Virol., 70, 2789, 10.1128/JVI.70.5.2789-2796.1996 Disney, 1990, A herpes simplex virus type 1 recombinant with both copies of the Vmw175 coding sequences replaced by the homologous varicella-zoster virus open reading frame, J. Gen. Virol., 71, 2681, 10.1099/0022-1317-71-11-2681 Docherty, 1999, Resveratrol inhibition of herpes simplex virus replication, Antiviral Res., 43, 145, 10.1016/S0166-3542(99)00042-X Docherty, 2004, Effect of topically applied resveratrol on cutaneous herpes simplex virus infections in hairless mice, Antiviral Res., 61, 19, 10.1016/j.antiviral.2003.07.001 Docherty, 2005, Effect of resveratrol on herpes simplex virus vaginal infection in the mouse, Antiviral Res., 67, 155, 10.1016/j.antiviral.2005.06.008 Donnelly, 2004, Anti-inflammatory effects of resveratrol in lung epithelial cells: molecular mechanisms, Am. J. Physiol. Lung Cell. Mol. Physiol., 287, L774, 10.1152/ajplung.00110.2004 Evers, 2004, 3,4′,5-Trihydroxy-trans-stilbene (resveratrol) inhibits human cytomegalovirus replication and virus-induced cellular signalling, Antiviral Res., 63, 85, 10.1016/j.antiviral.2004.03.002 Fukao, 2004, Effect of trans-resveratrol on the thrombogenicity and atherogenicity in apolipoprotein E-deficient and low-density lipoprotein receptor-deficient mice, Blood Coagul. Fibrinolysis, 15, 441, 10.1097/00001721-200408000-00001 Gilden, 2001, Presence of VZV and HSV-1 DNA in human nodose and celiac ganglia, Virus Genes, 23, 145, 10.1023/A:1011883919058 Gilman, 1980, Reaction patterns of herpes simplex virus type 1 and type 2 proteins with sera of patients with uterine cervical carcinoma and matched controls, Cancer Res., 40, 4640 Grose, 2005, Varicella vaccination of children in the United States: assessment after the first decade 1995–2005, J. Clin. Virol., 33, 89, 10.1016/j.jcv.2005.02.003 Heredia, 2000, Synergistic inhibition of HIV-1 in activated and resting peripheral blood mononuclear cells, monocyte-derived macrophages, and selected drug-resistant isolates with nucleoside analogues combined with a natural product, resveratrol, J. Acquir. Immune Defic. Syndr., 25, 246, 10.1097/00042560-200011010-00006 Jang, 1997, Cancer chemopreventative activity of resveratrol, a natural product derived from grapes, Science, 275, 218, 10.1126/science.275.5297.218 Kinchington, 1992, The varicella-zoster virus immediate-early protein IE62 is a major component of virus particles, J. Virol., 66, 359, 10.1128/JVI.66.1.359-366.1992 Krause, 1995, The nature of herpes zoster: a long-term study and new hypothesis, Proc. R. Soc. Med., 58, 9 Livak, 2001, Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method, Methods, 25, 402, 10.1006/meth.2001.1262 Marier, 2005, Production of ex vivo lipopolysaccharide-induced tumor necrosis factor-alpha, interleukin-1beta, and interleukin-6 is suppressed by trans-resveratrol in a concentration-dependent manner, Can. J. Vet. Res., 69, 151 Moriuchi, 1994, Varicella-zoster virus (VZV) virion-associated transactivator open reading frame 62 protein enhances the infectivity of VZV DNA, Virology, 200, 297, 10.1006/viro.1994.1190 Oxman, 2005, A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults, N. Engl. J. Med., 352, 2271, 10.1056/NEJMoa051016 Palamara, 2005, Inhibition of influenza A virus replication by resveratrol, J. Infect. Dis., 191, 1719, 10.1086/429694 Sato, 2003, Mutational analysis of open reading frames 62 and 71, encoding the varicella-zoster virus immediate-early transactivating protein, IE62, and effects on replication in vitro and in skin xenografts in the SCID-hu mouse in vivo, J. Virol., 77, 5607, 10.1128/JVI.77.10.5607-5620.2003 Schmidt, 1976, Improved yields of cell-free varicella-zoster virus, Infect. Immun., 14, 709, 10.1128/IAI.14.3.709-715.1976 Stankus, 2000, Management of herpes zoster (shingles) and postherpetic neuralgia, Am. Fam. Physician, 61, 2437 Takada, 2004, Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-kappaB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation, Oncogene, 23, 9247, 10.1038/sj.onc.1208169 Takahashi, 1975, Development of a live attenuated varicella vaccine, Biken. J., 18, 25 Takeuchi, 1991, An application of tetrazolium (MTT) colorimetric assay for screening of anti-herpes simplex virus compounds, J. Virol. Methods, 33, 61, 10.1016/0166-0934(91)90008-N Taylor, 2004, Roscovitine, a cyclin-dependent kinase inhibitor, prevents replication of varicella-zoster virus, J. Virol., 78, 2853, 10.1128/JVI.78.6.2853-2862.2004 Tyler, 1993, The DNA binding domain of the varicella-zoster virus gene 62 protein interacts with multiple sequences which are similar to the binding site of the related protein of herpes simplex virus type 1, Nucleic Acids Res., 21, 513, 10.1093/nar/21.3.513 Wang, 2005, Varicella-zoster virus activates inflammatory cytokines in human monocytes and macrophages via Toll-like receptor 2, J. Virol., 79, 12658, 10.1128/JVI.79.20.12658-12666.2005